At the International AIDS Conference in Rio de Janeiro, Brazil has placed a fundamental question before the global health community: can a nation that bore the burden of clinical trials be justly excluded from the medicines those trials produced? With 830,000 people living with HIV and transmission still rising among its most vulnerable populations, Brazil finds itself caught in a cruel paradox of development — too prosperous for the lowest-tier pricing, too constrained to afford what wealthier nations pay. The country's advocacy, amplified by Health Minister Padilha's declaration that 'innova
Brazil Demands Equitable Access to Long-Acting HIV Prevention Drugs
Brazil's 830,000 people living with HIV face continued barriers to access life-saving prevention technologies due to pricing and licensing exclusions.